Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia

被引:80
|
作者
Inskip, HM [1 ]
Kinlen, LJ
Taylor, AMR
Woods, CG
Arlett, CF
机构
[1] Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England
[2] Univ Oxford, Radcliffe Infirm, CRC, Canc Epidemiol Res Grp, Oxford OX2 6HE, England
[3] Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England
[4] St James Univ Hosp, Yorkshire Reg Genet Serv, Leeds LS9 7TF, W Yorkshire, England
[5] Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England
关键词
ataxia-telangiectasia; breast cancer; cancer mortality;
D O I
10.1038/sj.bjc.6690209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mortality from cancer among 178 parents and 236 grandparents of 95 British patients with ataxia-telangiectasia was examined. For neither parents nor grandparents was mortality from all causes or from cancer appreciably elevated over that of the national population. Among mothers, three deaths from breast cancer gave rise to a standardized mortality ratio of 3.37 (95% confidence interval (CI): 0.69-9.84). In contrast, there was no excess of breast cancer in grandmothers, the standardized mortality ratio being 0.89 (95% CI: 0.18-2.59), based on three deaths. This is the largest study of families of ataxia-telangiectasia patients conducted in Britain but, nonetheless, the study is small and Cis are wide. However, taken together with data from other countries, an increased risk of breast cancer among female heterozygotes is still apparent, though lower than previously thought.
引用
收藏
页码:1304 / 1307
页数:4
相关论文
共 50 条
  • [1] Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia
    H M Inskip
    L J Kinlen
    A M R Taylor
    C G Woods
    C F Arlett
    British Journal of Cancer, 1999, 79 : 1304 - 1307
  • [2] Cancer risk in heterozygotes for ataxia-telangiectasia
    Geoffroy-Perez, B
    Janin, N
    Ossian, K
    Laugé, A
    Croquette, MF
    Griscelli, C
    Debré, M
    Bressac-De-Paillerets, B
    Aurias, A
    Stoppa-Lyonnet, D
    Andrieu, N
    INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (02) : 288 - 293
  • [3] ATAXIA-TELANGIECTASIA HETEROZYGOTES AND CANCER
    AYMON, P
    CANCER JOURNAL - FRANCE, 1992, 5 (02): : 71 - 71
  • [4] BREAST AND OTHER CANCERS IN FAMILIES WITH ATAXIA-TELANGIECTASIA
    SWIFT, M
    REITNAUER, PJ
    MORRELL, D
    CHASE, CL
    NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (21): : 1289 - 1294
  • [5] The role of ataxia-telangiectasia heterozygotes in familial breast cancer
    Chen, JD
    Giesler, G
    Birkholtz, G
    Lindblom, P
    Rubio, C
    Lindblom, A
    CANCER RESEARCH, 1998, 58 (07) : 1376 - 1379
  • [6] Variation in breast cancer risk of heterozygotes for ataxia-telangiectasia according to environmental factors
    Geoffroy-Perez, B
    Janin, N
    Ossian, K
    Laugé, A
    Stoppa-Lyonnet, D
    Andrieu, N
    INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (04) : 619 - 623
  • [7] BREAST-CANCER AND OTHER CANCERS IN NORWEGIAN FAMILIES WITH ATAXIA-TELANGIECTASIA
    BORRESEN, AL
    ANDERSEN, TI
    TRETLI, S
    HEIBERG, A
    MOLLER, P
    GENES CHROMOSOMES & CANCER, 1990, 2 (04): : 339 - 340
  • [8] CANCER PREDISPOSITION OF ATAXIA-TELANGIECTASIA HETEROZYGOTES
    SWIFT, M
    CHASE, CL
    MORRELL, D
    CANCER GENETICS AND CYTOGENETICS, 1990, 46 (01) : 21 - 27
  • [9] WORKSHOP ON ATAXIA-TELANGIECTASIA HETEROZYGOTES AND CANCER
    BRIDGES, BA
    LENOIR, G
    TOMATIS, L
    CANCER RESEARCH, 1985, 45 (08) : 3979 - 3980
  • [10] Agreement of cardiovascular risk in ataxia-telangiectasia mutated heterozygotes and their children with Ataxia-telangiectasia
    Neves Barreto, Talita Lemos
    De Almeida Kotchetkoff, Elaine Cristina
    Aranda Lago, Carolina Sanchez
    Saccardo Sarni, Roseli Oselka
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (06): : 209 - 213